Press release
Sarcoidosis Pipeline Insights: Key Companies,Therapies, and Market Trends
Dive into DelveInsight's comprehensive report today! @ https://www.delveinsight.com/sample-request/sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Key Takeaways from the Sarcoidosis Pipeline Report
• In September 2025, Shares of aTyr Pharma dropped by more than 80% after its Phase III clinical trial in pulmonary sarcoidosis did not achieve its primary endpoint. In the EFZO-FIT trial, Efzofitimod failed to demonstrate an improvement in mean daily oral corticosteroid (OCS) dose at Week 48. Patients receiving 5.0 mg/kg efzofitimod experienced an average OCS dose reduction of 2.79 mg, compared with a 3.52 mg reduction observed in the placebo group.
• In May 2025, Prednisone was commonly recommended as the first-line therapy for pulmonary sarcoidosis, although its use is often associated with several undesirable side effects. New findings presented at ATS 2025 suggest that Methotrexate may serve as an effective alternative. Researchers reported that methotrexate demonstrated comparable disease control to prednisone while potentially offering a lower risk of side effects.
• In March 2025, aTyr Pharma announced a fourth favorable Data Safety Monitoring Board (DSMB) assessment for its Phase III EFZO-FIT trial evaluating efzofitimod in pulmonary sarcoidosis. The DSMB found no safety issues and advised that the study proceed as planned, with topline data anticipated in the third quarter of 2025.
• In March 2025, Xentria, Inc. announced that enrollment has been completed for its Phase Ia/IIb XTMAB16 clinical trial in pulmonary sarcoidosis, with 39 patients recruited across four countries. The randomized, placebo-controlled, dose-ranging study exceeded its original enrollment goals.
• DelveInsight's Sarcoidosis pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Sarcoidosis treatment.
• The leading Sarcoidosis Companies such as RELIEF THERAPEUTICS Holding SA , aTyr Pharma , Pfizer , United Therapeutics Corporation , Xentria, Inc. , Kyorin Pharmaceutical Co., Ltd, Novartis , Kinevant Sciences GmbH, Foresee Pharmaceuticals , AI Therapeutics, Molecure , and others.
• Promising Sarcoidosis Pipeline Therapies such as Efzofitimod, RLF-100, Abrocitinib, Inhaled Treprostinil, XTMAB-16, CMK389, Namilumab, FP-020, LAM001, OATD-01, and others.
Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ https://www.delveinsight.com/sample-request/sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
The Sarcoidosis Pipeline Report provides disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Sarcoidosis Pipeline Report also highlights the unmet needs with respect to Sarcoidosis.
Sarcoidosis Overview
The multisystem illness sarcoidosis, whose cause is uncertain, is typified by non-caseating granulomas in the organs. This disease primarily affects young individuals and is characterized by bilateral hilar lymphadenopathy and reticular opacities in the lungs.
Sarcoidosis Emerging Drugs Profile
Efzofitimod: aTyr Pharma
Efzofitimod is an investigational therapeutic candidate developed by aTyr Pharma for the treatment of pulmonary sarcoidosis. The drug is currently in Phase III stage of clinical trial evaluation to treat Sarcoidosis.
RLF-100: Relief Therapeutics
RLF-100 is an investigational therapeutic candidate developed by Relief Therapeutics for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.
Abrocitinib: Pfizer
Abrocitinib is an investigational therapeutic candidate developed by Pfizer for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.
Inhaled Treprostinil: United Therapeutics
Inhaled Treprostinil is an investigational therapeutic candidate developed by United Therapeutics for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.
XTMAB-16: Xentria, Inc.
XTMAB-16 is an investigational therapeutic candidate developed by Xentria, Inc. for the treatment of pulmonary sarcoidosis. The drug is currently in Phase Ia/IIb clinical trial evaluation to treat Sarcoidosis.
CMK389: Novartis
CMK389 is an investigational therapeutic candidate developed by Novartis for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.
Namilumab: Kinevant Sciences GmbH
Namilumab is an investigational therapeutic candidate developed by Kinevant Sciences GmbH for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.
FP-020: Foresee Pharmaceuticals
FP-020 is an investigational therapeutic candidate developed by Foresee Pharmaceuticals for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.
LAM001: AI Therapeutics
LAM001 is an investigational therapeutic candidate developed by AI Therapeutics for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.
OATD-01: Molecure
OATD-01 is an investigational therapeutic candidate developed by Molecure for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.
The Sarcoidosis Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Sarcoidosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sarcoidosis Treatment.
• Sarcoidosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sarcoidosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sarcoidosis market.
Explore groundbreaking therapies and clinical trials in the Sarcoidosis Pipeline @ https://www.delveinsight.com/sample-request/sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Sarcoidosis Companies
Relief Therapeutics, aTyr Pharma, Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharmaceutical Co., Ltd, Novartis, Kinevant Sciences GmbH, Foresee Pharmaceuticals, AI Therapeutics, Molecure, and others.
Sarcoidosis Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
• Oral
• Intravenous
• Subcutaneous
Sarcoidosis Products have been categorized under various Molecule types such as:
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Gene therapy
Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ https://www.delveinsight.com/sample-request/sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Scope of the Sarcoidosis Pipeline Report
• Coverage- Global
• Sarcoidosis Companies- RELIEF THERAPEUTICS Holding SA , aTyr Pharma , Pfizer , United Therapeutics Corporation , Xentria, Inc. , Kyorin Pharmaceutical Co., Ltd, Novartis , Kinevant Sciences GmbH, Foresee Pharmaceuticals , AI Therapeutics, Molecure , and others.
• Sarcoidosis Pipeline Therapies- Efzofitimod, RLF-100, Abrocitinib, Inhaled Treprostinil, XTMAB-16, CMK389, Namilumab, FP-020, LAM001, OATD-01, and others.
• Sarcoidosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Sarcoidosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Sarcoidosis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ https://www.delveinsight.com/sample-request/sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Table of Contents
1. Introduction
2. Executive Summary
3. Sarcoidosis: Overview
4. Pipeline Therapeutics
5. Comparative Analysis
6. Therapeutic Assessment
7. Sarcoidosis - DelveInsight's Analytical Perspective
8. Late Stage Products (Phase III)
9. Mid Stage Products (Phase II)
10. Early Stage Products (Phase I)
11. Preclinical Stage Products
12. Inactive Products
13. Sarcoidosis Key Companies
14. Sarcoidosis Key Products
15. Sarcoidosis - Unmet Needs
16. Sarcoidosis - Market Drivers and Barriers
17. Sarcoidosis - Future Perspectives and Conclusion
18. Sarcoidosis Analyst Views
19. Appendix
Contact Information
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: mmalhotra@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432, Las Vegas, NV, United States
Website: https://www.delveinsight.com
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sarcoidosis Pipeline Insights: Key Companies,Therapies, and Market Trends here
News-ID: 4531347 • Views: …
More Releases from Delveinsight Business Research LLP
Herpes Simplex Market Poised for Growth as Helicase-Primase Inhibitors Advance T …
DelveInsight's "Herpes Simplex Market Insights, Epidemiology and Market Forecast - 2036" report delivers an in-depth understanding of herpes simplex virus (HSV), historical and forecasted epidemiology, and market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
To know in detail about the herpes simplex market outlook, treatment uptake, and competitive landscape, click here: https://www.delveinsight.com/report-store/herpes-simplex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Some of the Key Facts of the Herpes Simplex Market Report
•…
Exocrine Pancreatic Insufficiency Market Set for Growth Through 2036 Amid Narrow …
DelveInsight's "Exocrine Pancreatic Insufficiency Market Insight, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of exocrine pancreatic insufficiency, historical and forecasted epidemiology, and market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
To know in detail about the exocrine pancreatic insufficiency market outlook, treatment uptake, and competitive landscape, click here: https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Some of the Key Facts of the Exocrine Pancreatic Insufficiency…
Common Warts Market Set to Grow Steadily Through 2036 as Immunotherapeutic Pipel …
DelveInsight's "Common Warts Market Insights, Epidemiology and Market Forecast - 2036" report delivers an in-depth understanding of common warts, historical and forecasted epidemiology, and market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
To know in detail about the common warts market outlook, treatment uptake, and competitive landscape, click here: https://www.delveinsight.com/report-store/common-warts-market-report?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Some of the Key Facts of the Common Warts Market Report
• The common…
Niemann Pick Disease Market Expected to Witness Significant Growth Through 2036, …
The Niemann Pick Disease market is anticipated to witness notable growth across the 7MM during the forecast period (2026-2036), driven by increasing disease awareness, improvements in genetic diagnosis, growing recognition of lysosomal storage disorders, and the advancement of promising disease-modifying therapies. The emergence of investigational candidates such as Nizubaglustat (AZ-3102) (Azafaros A.G.) and Trappsol Cyclo (hydroxypropyl-beta-cyclodextrin) (Cyclo Therapeutics) is expected to transform the treatment landscape by addressing the significant unmet…
More Releases for Sarcoidosis
Sarcoidosis Therapeutics Market Is Going to Boom |• Amgen • Celgene • GSK
Worldwide Market Reports has recently published an in-depth research study titled "Sarcoidosis Therapeutics Market Size and Forecast 2026-2033: Analysis by Manufacturers, Key Regions, Product Types, and Applications." The report is developed using a robust blend of primary and secondary research methodologies, ensuring accuracy, reliability, and comprehensive market coverage. Leveraging historical data and forward-looking projections, the study presents a detailed evaluation of the Sarcoidosis Therapeutics market growth, analyzing trends in both…
Emerging Trends to Reshape the Sarcoidosis Drug Market: Innovation In Sarcoidosi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Sarcoidosis Drug Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for sarcoidosis drugs has experienced substantial growth in the recent past. The market size is predicted to escalate from $7.43 billion in 2024 to $7.88 billion in 2025, exhibiting a compound annual growth…
Sarcoidosis Market Massive Growth opportunity Ahead
Introduction
Sarcoidosis is a rare, multisystem inflammatory disease characterized by the formation of granulomas in organs such as the lungs, skin, eyes, and lymph nodes. Although its exact cause remains unknown, it is believed to be linked to immune system overactivation, genetic predisposition, and environmental triggers. While many cases resolve spontaneously, chronic sarcoidosis can cause severe complications, particularly in pulmonary and cardiac systems.
The global sarcoidosis market is gaining attention as healthcare…
Sarcoidosis Market Set to Eyewitness Substantial Growth by 2024-2031
The Latest research report on the Sarcoidosis Market 2024 provides a comprehensive analysis of the current market landscape, with forecasts extending to 2031. This study combines qualitative and quantitative insights to highlight significant market developments, challenges, competitive dynamics, and potential opportunities and trends shaping the Sarcoidosis Market. The report covers market size, recent trends, growth projections, market share, and development status. Additionally, it examines government policies, market dynamics, cost structures,…
Pulmonary Sarcoidosis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Pulmonary Sarcoidosis Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Pulmonary Sarcoidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Pulmonary…
Sarcoidosis Drugs Market Size, Future Growth, Segments Forecast 2022-2028
Precision Business Insights published a research report on " Sarcoidosis Drug Market: By Product Type (Tumor Necrosis Factor Alpha (TNF-α) Inhibitors, Corticosteroids, Immunosuppressant Drugs, Others), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography - Global/Region/Country Forecast to 2028"
Sarcoidosis is an inflammatory disorder characterised by the growth of small collections of inflammatory cells. It can affect any organ in the body,…
